Palo Alto-based oncology AI startup Risa Labs has secured $3.5 million in funding to scale its cutting-edge healthcare automation platform, BOSS, aiming to enhance cancer care delivery across the United States.
In a major boost for healthtech innovation, Risa Labs, a Palo Alto, California-based oncology-focused AI company, has announced the successful raise of $3.5 million in a recent funding round. The round was led by Binny Bansal, co-founder of Flipkart, with strong participation from Oncology Ventures, General Catalyst, z21 Ventures, ODD BIRD VC, and veteran investor Ashish Gupta.
Expanding Access to AI-Driven Cancer Treatment Workflows
The newly raised capital will be utilized to accelerate the deployment of Risa Labs’ flagship platform, BOSS, across 100 cancer centers in the U.S. within the next two years. The expansion reflects the company’s mission to transform oncology workflows using AI and address long-standing delays in cancer care delivery.
What is BOSS? The AI Backbone of Oncology Workflow Automation
Risa Labs’ platform, BOSS (Better Oncology System Services), is an AI-powered SaaS workflow automation tool designed specifically for oncology centers. Built by co-founders Kshitij Jaggi and Kumar Shivang, BOSS aims to remove the bottlenecks in cancer care management by replacing traditional, fragmented systems with a digitally intelligent, automated parallel workforce.
BOSS leverages a sophisticated combination of agentic AI, digital twins, large language models (LLMs), and reinforcement learning. These technologies work in tandem to deconstruct complex medical workflows into micro-tasks, and assign them to an intelligent digital ecosystem that functions both independently and alongside healthcare teams.
This parallel system integrates seamlessly with an institution’s software stack, significantly reducing administrative overload, improving patient throughput, and minimizing treatment delays—a critical factor in effective cancer management.
Addressing a Critical Need in Modern Oncology
Delays in cancer diagnosis and treatment remain a persistent challenge across global healthcare systems. With the increasing volume of cases and administrative strain, Risa Labs’ AI-led automation brings much-needed relief to clinical teams while enhancing operational efficiency and improving patient outcomes.
“Our vision is to transform how oncology centers operate by bringing a reliable, intelligent digital workforce into the system,” said Kshitij Jaggi, co-founder and CEO of Risa Labs. “With the support of visionary investors and domain experts, we are well-positioned to bring this innovation to scale.”
Strategic Investors Backing Healthtech Disruption
This funding round highlights growing investor confidence in AI-led healthtech solutions. Binny Bansal’s backing adds significant credibility, while participation from specialized firms like Oncology Ventures underscores the market potential of sector-specific SaaS platforms in healthcare.
The support of General Catalyst, known for backing transformative tech companies, further strengthens Risa Labs’ go-to-market strategy and product development roadmap.
Looking Ahead: AI in Oncology is Just Getting Started
As Risa Labs gears up to deploy BOSS in 100 cancer centers nationwide, the company is poised to become a leader in AI-based oncology infrastructure. Their work represents a critical step toward smarter, faster, and more personalized cancer care, aligning with the broader vision of data-driven, patient-centric healthcare.